ESMs, a proteome-scale framework to classify loss-of-function missense variants into distinct mechanistic groups by combining two complementary state-of-the-art machine learning models. The strength ...

MSD is scrapping a £1 billion ($1.35 billion) expansion of its UK operations – including a facility already under construction in London – saying the country does not value innovative medicines. The ...